Crohn’s Disease | Unmet Need | US/EU | 2024

TNF-alpha inhibitors (e.g., Remicade, Humira) are the mainstay of biological treatment for moderate to severe Crohn’s disease (CD), while non-TNF biologics (i.e., Takeda’s Entyvio, a CAM inhibitor; Johnson & Johnson Innovative Medicine’s Stelara, an IL-12/23 inhibitor; and AbbVie’s Skyrizi, an IL-23 inhibitor and Rinvoq, a JAK inhibitor) are mostly used as later-line therapies, following anti-TNF failure. These agents have safety risks and efficacy limitations, and the launch of biosimilar alternatives has only increased the complexity of CD treatment. Meanwhile, significant need remains, especially in the treatment of patients with CD refractory to available therapies and those with fistulizing disease.

QUESTIONS ANSWERED

• What are the treatment drivers and goals for moderate to severe CD?
• Which drug attributes are key influences, which have limited impact, and which are hidden opportunities?
• How do current therapies perform on key treatment drivers and goals for moderate to severe CD?
• What are the prevailing areas of unmet need and opportunity in moderate to severe CD?
• What trade-offs across different clinical attributes and price are acceptable to U.S. and European gastroenterologists for a hypothetical new moderate to severe CD drug?

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP Simulator.

KEY FEATURE

The Target Product Profile (TPP) Simulator tool allows for customizable market simulations based on conjoint analysis that depicts how physicians make decisions based on actual behavior rather than opinion. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.

Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, France, Germany, United Kingdom

Primary research: Survey of 61 U.S. and 31 European gastroenterologists fielded in December 2023

Key companies: AbbVie, Johnson & Johnson Innovative Medicine, Takeda, UCB, Celltrion Healthcare

Key drugs: Remicade, infliximab biosimilar (IV), Entyvio, Stelara, Skyrizi, Rinvoq, Humira, adalimumab biosimilar, Remsima SC